Showing 1621-1630 of 1735 results for "".
- PolyActiva Completes Initial Clinical Trial With Latanoprost FA SR Ocular Implant for 6-Month Glaucoma Treatmenthttps://modernod.com/news/polyactiva-completes-initial-clinical-trial-with-latanoprost-fa-sr-ocular-implant-for-6-month-glaucoma-treatment/2478494/PolyActiva announced it has successfully completed its phase I clinical study for its lead candidate, the Latanoprost FA SR Ocular Implant. The device was well tolerated in all 8 patients with no significant safety findings. The study also showed that the implant persists for the entire 6-
- Tarsus Pharmaceuticals Announces Closing of Initial Public Offeringhttps://modernod.com/news/tarsus-pharmaceuticals-announces-closing-of-initial-public-offering/2478442/Tarsus Pharmaceuticals announced the closing of its initial public offering of 6,325,000 shares of its common stock at a price to the public of $16.00 per share, which includes 825,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares of common stock. All of
- Low Vision Resources and Rehabilitation for Retinal Degeneration Patients: A Webinar to Discuss Critical Needs and Opportunitieshttps://modernod.com/news/low-vision-resources-and-rehabilitation-for-retinal-degeneration-patients-a-webinar-to-discuss-critical-needs-and-opportunities/2478431/The Foundation Fighting Blindness is hosting a low vision webinar to inform eye care professionals about the many opportunities to greatly enhance the quality of life, and provide hope, for their retinal disease patients. The interactive webinar is appropriate for all eye care professional
- J&J Pauses COVID-19 Vaccine Studies After “Unexplained Illness”https://modernod.com/news/jj-pauses-covid-19-vaccine-studies-after-unexplained-illness/2478407/Johnson & Johnson confirmed that it paused further dosing in all clinical studies of its COVID-19 vaccine candidate JNJ-78436735, including the phase 3 ENSEMBLE trial, due to an “unexplained illness” in a participant. The company noted that the subject’s illness is being rev
- Biotech Healthcare Launches Optiflex TRIO Trifocal IOL in Europehttps://modernod.com/news/biotech-healthcare-launches-optiflex-trio-trifocal-iol/2478350/Switzerland-based Biotech Healthcare has announced the European launch of the Optiflex Trio, a diffractive-refractive trifocal toric IOL designed to treat presbyopia and with astigmatism. Its unique diffraction pattern gives a balanced light distribution at all three distances: near, intermediate
- Bausch Health Acquires Option To Purchase Ophthalmology Assets Of Allegro Ophthalmicshttps://modernod.com/news/bausch-health-to-acquire-option-to-purchase-all-ophthalmology-assets-of-allegro-ophthalmics/2478300/Bausch Health has entered into an agreement to acquire an option to purchase all ophthalmology assets of Allegro Ophthalmics, including global rights for risuteganib (Luminate)1, Allegro’s lead investigational compound in retina. Full financial terms of the deal were not d
- MetLife to Acquire Versant Health, Owner of Davis Vision and Superior Visionhttps://modernod.com/news/metlife-to-acquire-versant-health-owner-of-davis-vision-and-superior-vision/2478292/MetLife announced it has entered into a definitive agreement to acquire Versant Health from an investor group led by Centerbridge Partners and including FFL Partners for approximately $1.675 billion in an all-cash transaction. Versant Health owns the marketplace brands Davis Vision and Superior V
- Santen Acquires Eyevance Pharmaceuticalhttps://modernod.com/news/santen-acquires-eyevance-pharmaceutical/2478289/In a move to enter the US pharmaceuticals market and expand its global presence, Santen announced it has acquired Eyevance Pharmaceutical for $225 million in cash. In the deal, Santen Holdings U.S. Inc., a wholly-owned subsidiary of Santen, will acquire all of the outstanding shares of Ey
- Analysis Finds Corticosteroids Cut Risk of Death in Critically Ill COVID-19 Patientshttps://modernod.com/news/analysis-finds-corticosteroids-cut-risk-of-death-in-critically-ill-covid-19-patients/2478240/Results of a meta-analysis published Wednesday in JAMA suggest that the use of systemic corticosteroids in critically ill patients with COVID-19 is associated with lower 28-day all-cause mortality compared to usual care or placebo. Study author Jonathan Sterne noted that the benefit was
- Zeiss Launches Virtual Optometry Hubhttps://modernod.com/news/zeiss-launches-virtual-optometry-hub/2478226/Zeiss announced it is launching the Zeiss Virtual Optometry Hub on September 20-21. In the all-new 360° experience, visitors will be able to take a walk through the Zeiss Virtual Practice and see how diagnostic equipment and data management can integrate seamlessly to provide a sophisticated prac